Literature DB >> 23944322

Bilateral toxoplasmosis retinitis associated with ruxolitinib.

Roger A Goldberg, Elias Reichel, Lauren J Oshry.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23944322     DOI： 10.1056/NEJMc1302895

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  39 in total

1.  Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function.

Authors:  F Perner; T M Schnöder; S Ranjan; D Wolleschak; C Ebert; M C Pils; S Frey; A Polanetzki; C Fahldieck; U Schönborn; B Schraven; B Isermann; T Fischer; F H Heidel
Journal:  Leukemia       Date:  2015-08-05       Impact factor: 11.528

Review 2.  Immunological Consequences of JAK Inhibition: Friend or Foe?

Authors:  Donal P McLornan; Alesia A Khan; Claire N Harrison
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 3.  Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.

Authors:  Brady L Stein; Jason Gotlib; Murat Arcasoy; Marie Huong Nguyen; Neil Shah; Alison Moliterno; Catriona Jamieson; Daniel A Pollyea; Bart Scott; Martha Wadleigh; Ross Levine; Rami Komrokji; Rebecca Klisovic; Krishna Gundabolu; Patricia Kropf; Meir Wetzler; Stephen T Oh; Raul Ribeiro; Rita Paschal; Sanjay Mohan; Nikolai Podoltsev; Josef Prchal; Moshe Talpaz; David Snyder; Srdan Verstovsek; Ruben A Mesa
Journal:  J Natl Compr Canc Netw       Date:  2015-04       Impact factor: 11.908

Review 4.  The Rationale for Immunotherapy in Myeloproliferative Neoplasms.

Authors:  Lucia Masarova; Prithviraj Bose; Srdan Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2019-08       Impact factor: 3.952

5.  Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib.

Authors:  M Massa; V Rosti; R Campanelli; G Fois; G Barosi
Journal:  Leukemia       Date:  2013-10-22       Impact factor: 11.528

Review 6.  Efficacy of ruxolitinib for myelofibrosis.

Authors:  Fabio P S Santos; Srdan Verstovsek
Journal:  Expert Opin Pharmacother       Date:  2014-05-24       Impact factor: 3.889

7.  JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis.

Authors:  T Stübig; H Alchalby; M Ditschkowski; D Wolf; G Wulf; T Zabelina; C Wolschke; F Ayuk; N Kröger
Journal:  Leukemia       Date:  2014-02-26       Impact factor: 11.528

8.  Disseminated tuberculosis associated with ruxolitinib.

Authors:  R K Hopman; S J Lawrence; S T Oh
Journal:  Leukemia       Date:  2014-03-13       Impact factor: 11.528

Review 9.  JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.

Authors:  Lorraine Springuel; Jean-Christophe Renauld; Laurent Knoops
Journal:  Haematologica       Date:  2015-10       Impact factor: 9.941

Review 10.  Clinical potential of pacritinib in the treatment of myelofibrosis.

Authors:  Ana B Duenas-Perez; Adam J Mead
Journal:  Ther Adv Hematol       Date:  2015-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.